Cognitive function and retinal biomarkers as novel approach to diagnosing and assessing autism spectrum disorder
Lower blood ADAM10 and CNTF mirror autism severity, giving BCBAs a possible lab partner to behavioral data.
01Research in Context
What this study did
The team drew blood from kids with autism and from neurotypical kids. They measured two proteins: ADAM10 and CNTF. These proteins help keep eye and brain cells healthy.
They wanted to know if the levels matched how severe the autism traits were.
What they found
Children with autism had lower ADAM10 than the comparison group. Lower ADAM10 and CNTF went hand-in-hand with higher autism severity scores.
The blood test gave a clear signal: less protein, more support needs.
How this fits with other research
Heuer et al. (2008) saw the same pattern with antibodies: lower blood IgG and IgM tracked worse behavior. Agiovlasitis et al. (2025) now shows the rule holds for retinal proteins too.
Efe et al. (2021) also used a quick plasma test, but their oxidative-stress marker only flagged who had autism; it did not rise or fall with severity. The new study extends that line by giving a severity dial, not just a yes-or-no light.
Nicotera et al. (2019) found EEG scars linked to tougher symptoms. Plasma or brain waves—both give you a severity clue, so you can pick the tool that fits your clinic.
Why it matters
You already watch behavior to gauge progress. Adding a five-minute blood draw could give you a number that moves with treatment gains or losses. If ADAM10 edges up while skills improve, you have extra evidence that your plan is working. Ask the pediatrician to add ADAM10 and CNTF to routine labs; track them at intake and every six months. One tube, one data line, clearer decisions.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add ADAM10 and CNTF to the medical request sheet and plot the scores next to your VB-MAPP or AFLS graphs.
02At a glance
03Original abstract
The retina is invariably considered an extension of the central nervous system and can predict cognitive impairment in neurodevelopmental and neurodegenerative disorders. This is due to the physiological and embryological link between the retina and the brain. Since this correlation was not previously tested in autism spectrum disorder (ASD), we aim to provide evidence for a correlation between retinal dysfunction and cognitive impairment in ASD children through previously reported retina and cognitive dysfunction biomarkers. 80 children were recruited to test biomarkers of the retinal function, Ciliary neurotrophic factor (CNTF), and cognitive function A Disintegrin and Metalloproteases 10 (ADAM10). These biomarkers were correlated with the Childhood Autism Rating Score (CARS) to distinguish ASD from cognitive impairment disorders and the Short Sensory Profile (SSP) as a sensory impairment indicator, including vision. ADAM10 was significantly decreased in ASD children compared to neurotypical children (p < 0.01). It also decreased as the severity of autism increased, as measured by CARS. We also found that CNTF decreases in ASD children with moderate severity compared to neurotypical and severe ASD groups, indicating that CNTF can be an early indicator of ASD. ADAM10 was directly related to CNTF, implying the direct correlation between the eye and cognitive function in ASD. ADAM10 is a potential indicator of cognitive function in ASD, and CNTF can be an indicator of retina function. The relationship between both biomarkers might serve as early diagnosis biomarkers and a potential therapeutic target in ASD.
, 2025 · doi:10.1038/s41598-025-03062-z